{"id":390691,"date":"2018-05-04T00:00:00","date_gmt":"2018-05-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfcg0001-2018-biopharma-friedreichs-ataxia-niche-rare-disease-landscape-forecast-us-eu5-2018\/"},"modified":"2026-04-22T23:27:54","modified_gmt":"2026-04-22T23:27:54","slug":"nrlfcg0001-2018-biopharma-friedreichs-ataxia-niche-rare-disease-landscape-forecast-us-eu5-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfcg0001-2018-biopharma-friedreichs-ataxia-niche-rare-disease-landscape-forecast-us-eu5-2018\/","title":{"rendered":"Friedreich&#8217;s Ataxia | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2018"},"content":{"rendered":"<p>Friedreich\u2019s ataxia (FA) is a progressive, autosomal recessive, neurodegenerative disease characterized by slowly advancing ataxia (loss of bodily control). No treatments are currently approved for FA; thus, patients rely on a combination of off-label therapies targeted to specific symptoms, over-the-counter antioxidants, and nonpharmacological interventions to manage their disease. Despite the high unmet need for effective treatments, the late-stage FA pipeline is sparse; the most advanced agents are only in Phase II. However, optimism remains high among thoughtleaders as technological breakthroughs in molecular biology and gene-editing techniques are spurring early-stage development in FA. Given the lack of current therapies for FA, significant commercial opportunity remains for any agent that can alleviate the disease\u2019s symptoms or modify its course.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large is the diagnosed prevalent FA population in the United States and EU5? How will the population change through 2027?<\/li>\n<li>What is the current treatment landscape for FA patients, and how will it change in the next ten years?<\/li>\n<li>What clinical needs remain unfulfilled?<\/li>\n<li>Which emerging therapies do neurologists consider most promising, and which are likely to launch by 2027? What will be the commercial impact of these new FA therapies?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast: comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390691","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-friedreichs-ataxia","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390691\/revisions"}],"predecessor-version":[{"id":576738,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390691\/revisions\/576738"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}